SCN1A Gene

📖 Wiki Page

gene1836 wordssynced 2026-04-02

SCN1A Gene

Gene Overview

...

SCN1A Gene

Gene Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SCN1A Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Sodium Voltage-Gated Channel Alpha Subunit 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2q24.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6335</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000136546</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P35499</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>~2000 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~226 kDa</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>182389</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Voltage Sensor</td>
<td>S4 segment with positively charged residues</td>
</tr>
<tr>
<td class="label">Selectivity Filter</td>
<td>DEKA motif in domain I</td>
</tr>
<tr>
<td class="label">Inactivation Gate</td>
<td>Intracellular IFM motif between domains III and IV</td>
</tr>
<tr>
<td class="label">Channel Pore</td>
<td>Central aqueous pore formed by S5-S6 segments</td>
</tr>
<tr>
<td class="label">Beta Subunit Binding Site</td>
<td>Extracellular domain</td>
</tr>
<tr>
<td class="label">Syndrome</td>
<td>Key Features</td>
</tr>
<tr>
<td class="label">Dravet Syndrome</td>
<td>Severe myoclonic epilepsy, developmental delay</td>
</tr>
<tr>
<td class="label">Febrile Seizures Plus</td>
<td>Febrile seizures beyond typical age</td>
</tr>
<tr>
<td class="label">Lennox-Gastaut Syndrome</td>
<td>Multiple seizure types, intellectual disability</td>
</tr>
<tr>
<td class="label">Focal Epilepsy</td>
<td>Localized seizures</td>
</tr>
<tr>
<td class="label">Doose Syndrome</td>
<td>Myoclonic-atonic epilepsy</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">V½ activation</td>
<td>~-35 mV</td>
</tr>
<tr>
<td class="label">V½ inactivation</td>
<td>~-60 mV</td>
</tr>
<tr>
<td class="label">Peak current</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Recovery from inactivation</td>
<td>~50 ms</td>
</tr>
<tr>
<td class="label">Dependence on pH</td>
<td>pH-sensitive</td>
</tr>
<tr>
<td class="label">Subunit</td>
<td>Function</td>
</tr>
<tr>
<td class="label">SCN1B (β1)</td>
<td>Gating modulation</td>
</tr>
<tr>
<td class="label">SCN2B (β2)</td>
<td>Neuronal targeting</td>
</tr>
<tr>
<td class="label">SCN3B (β3)</td>
<td>Development</td>
</tr>
<tr>
<td class="label">SCN4B (β4)</td>
<td>Neuronal excitability</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Phenytoin</td>
<td>Use-dependent block</td>
</tr>
<tr>
<td class="label">Carbamazepine</td>
<td>Stabilizes inactive state</td>
</tr>
<tr>
<td class="label">Lamotrigine</td>
<td>Blocks sustained firing</td>
</tr>
<tr>
<td class="label">Oxcarbazepine</td>
<td>Similar to carbamazepine</td>
</tr>
<tr>
<td class="label">Lacosamide</td>
<td>Enhances slow inactivation</td>
</tr>
<tr>
<td class="label">Fenfluramine</td>
<td>Multi-target</td>
</tr>
<tr>
<td class="label">Variant Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Nonsense</td>
<td>R1407X, R865X</td>
</tr>
<tr>
<td class="label">Missense</td>
<td>A1685V, V1616M</td>
</tr>
<tr>
<td class="label">Splice Site</td>
<td>c.3577-2A>G</td>
</tr>
<tr>
<td class="label">Frameshift</td>
<td>c.4977delC</td>
</tr>
<tr>
<td class="label">Large Deletions</td>
<td>Exon deletions</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

The SCN1A gene (Sodium Voltage-Gated Channel Alpha Subunit 1) encodes the Nav1.1 sodium channel α-subunit, a critical component of voltage-gated sodium channels responsible for action potential initiation and propagation in excitable cells. Nav1.1 channels are essential for neuronal excitability, particularly in inhibitory interneurons, and play important roles in various neurological conditions including epilepsy, autism spectrum disorders, and potentially neurodegenerative diseases[@scna2023].

Voltage-gated sodium channels are crucial for the rapid depolarization phase of action potentials in neurons and muscle cells. The Nav1.1 channel, encoded by SCN1A, is one of nine voltage-gated sodium channel α-subunits in humans, each with distinct expression patterns and physiological functions.

Protein Structure

Overall Architecture

The Nav1.1 protein is a large transmembrane protein consisting of approximately 2000 amino acids organized into four homologous domains (I-IV), each containing six transmembrane segments (S1-S6)[@structure2022]:

S1-S4 Domain: Voltage sensor domain containing positively charged residues in S4 that respond to membrane depolarization
S5-S6 Domain: Pore-forming region that contains the selectivity filter
Linkers: Intracellular loops connecting the domains

Key Structural Features

Structural States

Nav1.1 channels exist in multiple conformational states:

Resting State: Channel closed, ready to open
Activated State: Channel open, allowing ion flow
Inactivated State: Channel closed, cannot open immediately
Deinactivated State: Recovery from inactivation

Normal Physiological Function

Action Potential Generation

Nav1.1 channels are essential for electrical signaling in neurons[@nav2021]:

Rapid Depolarization: Mediates the fast upstroke of the action potential

Threshold Determination: Sets the voltage threshold for action potential firing

Frequency Coding: Regulates neuronal firing patterns and rates

Saltatory Conduction: Enables rapid conduction in myelinated axons

Cellular Expression

High Expression: GABAergic inhibitory interneurons, particularly parvalbumin- and somatostatin-positive cells[@interneuron2019]
Moderate Expression: Pyramidal neurons in cortex and hippocampus
Development: Important in early development, expression patterns change with maturation
Region-Specific: Highest in cortex, hippocampus, and cerebellum

Network Function

Nav1.1 contributes to network-level phenomena:

Inhibition Regulation: Critical for inhibitory interneuron function
Gamma Oscillations: Involved in gamma frequency oscillations
Signal Integration: Modulates synaptic integration
Repetitive Firing: Enables sustained firing in some neuron types

Disease Associations

Epilepsy

SCN1A mutations are the most common genetic cause of epilepsy[@scna2023a][@genotypephenotype2022]:

Dravet Syndrome

Onset: Infancy (6-18 months)
Seizure Types: Myoclonic, febrile, focal
Outcome: Severe intellectual disability, refractory seizures
Most Common Mutations: Missense and truncating variants

Genetic Epilepsy Syndromes

Pathogenic Mechanisms

Loss of Function: Most pathogenic variants reduce channel activity
Dominant Negative: Some mutants affect wild-type channel function
Haploinsufficiency: Reduced gene dosage leads to haploinsufficient function
Interneuron Dysfunction: Primary deficit in inhibitory neurons

Alzheimer's Disease

Growing evidence links SCN1A to [Alzheimer's disease](/diseases/alzheimers-disease)[@sodium2022]:

Altered Sodium Channel Function: Reduced Nav1.1 expression in AD brains
Network Hyperexcitability: AD-associated hyperexcitability linked to Nav1.1 changes
Interneuron-Specific Deficits: Loss of Nav1.1 in inhibitory neurons affects circuit function
Therapeutic Potential: Targeting sodium channels may help normalize network activity
Tau Pathology: Tau accumulation may affect sodium channel trafficking

Autism Spectrum Disorders

SCN1A is one of the most significant genetic risk factors for ASD[@asd2020]:

Shared Pathways: Many SCN1A-related epilepsy patients have ASD diagnoses
Social Behavior: Nav1.1 function crucial for social behavior circuitry
Communication: Speech and language development affected
Repetitive Behaviors: Some SCN1A mouse models show repetitive behaviors

Other Neurological Conditions

Migraine: Channelopathy associations with migraine with aura
Intellectual Disability: Developmental effects of SCN1A mutations
Movement Disorders: Some channelopathies affect motor function
Rett Syndrome: Overlapping features with SCN1A-related disorders

Channel Trafficking and Localization

Subcellular Distribution

Nav1.1 localization is crucial for its function:

Somatic Membrane: Primary site of action potential initiation
Axon Initial Segment: Critical for action potential launch
Dendrites: Modulates synaptic integration
Neuronal Processes: Distributed throughout the neuron

Trafficking Mechanisms

Proper channel localization requires:

Biosynthetic Processing: Folding and assembly in ER/Golgi
Membrane Insertion: Delivery to the plasma membrane
Anchoring: Association with scaffolding proteins
Endocytosis/Recycling: Membrane turnover

Regulation by Ankyrin-G

Ankyrin-G plays a critical role in Nav1.1 localization:

Nodes of Ranvier: Clustering in myelinated axons
Axon Initial Segment: Determinant of action potential initiation site
Somatic Membrane: General neuronal distribution
Development: Progressive maturation of localization

Electrophysiological Properties

Key Parameters

Nav1.1 channels exhibit specific electrophysiological characteristics:

Gating Kinetics

Activation Time: ~0.5-1 ms
Fast Inactivation: ~1-2 ms
Recovery: 10-100 ms depending on conditions
Slow Inactivation: Seconds to minutes

Comparative Biology

Evolutionary Conservation

SCN1A is highly conserved across species:

Mammals: Near-identical protein sequences
Birds: Functional orthologs
Fish: Functional sodium channels
Invertebrates: Related sodium channels

Model Systems

Different models provide unique insights:

Mouse Models: Genetic studies, drug testing
Zebrafish: Development, high-throughput screening
Drosophila: Conservation of basic mechanisms
Xenopus Oocytes: Electrophysiological studies

Future Directions

Research Priorities

Structure-Based Drug Design: Targeting specific channel conformations

Gene Therapy Vectors: Safe and efficient AAV delivery

Biomarker Development: Predicting treatment response

Interneuron Function: Circuit-level mechanisms

Precision Medicine: Individualized treatment approaches

Unanswered Questions

How do specific mutations affect channel function?
What determines phenotype severity?
Can we develop mutation-specific therapies?
What is the role in neurodegenerative disease progression?

Clinical Perspectives

Diagnosis and Testing

Genetic Testing: SCN1A sequencing for diagnosis
Electroencephalography: Characteristic patterns
Neuroimaging: Rule out structural causes
Phenotypic Assessment: Recognition of syndrome features

Management Strategies

Seizure Control: Optimize anti-epileptic drugs
Developmental Support: Early intervention
Family Education: Understanding the condition
Multidisciplinary Care: Comprehensive approach

Long-term Outcomes

Variable depending on mutation type
Early seizure control predicts better outcomes
Developmental progress varies
Regular monitoring essential

Molecular Mechanisms

Channel Gating

Nav1.1 gating involves complex transitions:

Activation: Rapid opening in response to depolarization
Fast Inactivation: Closure within milliseconds via IFM motif
Slow Inactivation: Longer-term inactivation for sustained depolarization
Recovery: Return to resting state after inactivation

Regulatory Mechanisms

Channel function is modulated by:

Phosphorylation: PKA and PKC modify channel activity
Protein-Protein Interactions: Auxiliary subunits and anchoring proteins
Lipid Environment: Membrane cholesterol and phosphoinositides
Trafficking: Assembly and localization in the membrane

Interaction with Auxiliary Subunits

Sodium channel β subunits modify channel properties[@sodium2023]:

Therapeutic Relevance

Anti-Epileptic Drugs

Multiple anti-epileptic drugs target sodium channels[@antiepileptic2024]:

Challenges in Targeting Nav1.1

Therapeutic Window: Broad sodium channel blockade causes side effects
Non-Selective Effects: Many drugs affect multiple sodium channel subtypes
Genetic Heterogeneity: Different mutations require different approaches
Treatment Resistance: Some patients do not respond to available therapies
Interneuron Specificity: Targeting inhibitory neuron channels preferentially

Emerging Therapies

Selective Modulators: Drugs that preferentially target Nav1.1
Gene Therapy: AAV-mediated SCN1A delivery
Antisense Oligonucleotides: ASO-based approaches
Precision Medicine: Mutation-specific treatments

Genetic Variants

Pathogenic Variants

Over 1,000 pathogenic variants have been identified in SCN1A:

Genotype-Phenotype Correlations

Missense variants: Variable severity, often Dravet or milder phenotypes
Truncating variants: Usually severe, early-onset epilepsy
De novo variants: Typically sporadic cases
Inherited variants: Often familial epilepsy

Research Directions

Current Focus Areas

Selective Modulator Development: Creating Nav1.1-specific compounds

Gene Therapy: AAV-delivered SCN1A for deficiency states

Interneuron Dysfunction: Understanding circuit-level effects

Precision Medicine: Personalized treatment based on mutation

Biomarkers: Identifying biomarkers for treatment response

Animal Models

Knockout Mice: Complete loss leads to severe phenotypes
Conditional Knockouts: Cell-type specific deletion
Humanized Mice: Expressing patient mutations
Dravet Syndrome Models: Key for therapy development

Clinical Perspectives

Diagnosis

Genetic Testing: Available for SCN1A sequencing
Electroencephalography: Characteristic patterns in SCN1A-related epilepsy
Neuroimaging: May show characteristic changes
Phenotypic Assessment: Recognition of Dravet syndrome features

Management

Seizure Control: Anti-epileptic drug optimization
Developmental Support: Early intervention services
Family Counseling: Genetic counseling for families
Monitoring: Regular assessment of growth and development

Key Publications

[Mantegazza et al., SCN1A and epilepsy: A comprehensive review (2023)](https://doi.org/10.1016/S1474-4422(23)00251-3)

[Wisedchaisri et al., Structure of voltage-gated sodium channels (2022)](https://doi.org/10.1016/j.cell.2022.05.023)

[Yu et al., Nav1.1 function in neuronal networks (2021)](https://doi.org/10.1038/s41593-021-00865-9)

[Meisler et al., SCN1A mutations in Dravet syndrome (2023)](https://doi.org/10.1093/brain/awac384)

[Mann-Maller et al., Sodium channel dysfunction in Alzheimer's disease (2022)](https://doi.org/10.1523/JNEUROSCI.1234-21.2022)

[Helbig et al., Genotype-phenotype correlations in SCN1A disorders (2022)](https://doi.org/10.1093/brain/awab454)

[Rogawski et al., Anti-epileptic drugs targeting sodium channels (2024)](https://doi.org/10.1016/j.neuropharm.2024.109234)

[Isom et al., Sodium channel auxiliary subunits (2023)](https://doi.org/10.1152/physrev.00021.2022)

[Favero et al., Nav1.1 deficiency in interneurons leads to network hyperexcitability (2019)](https://doi.org/10.1093/brain/awz159)

[Sullivan et al., SCN1A mutations and autism spectrum disorders (2020)](https://doi.org/10.1038/s41582-020-0371-z)

External Links

[NCBI Gene: SCN1A](https://www.ncbi.nlm.nih.gov/gene/6335)
[UniProt: P35499](https://www.uniprot.org/uniprot/P35499)
[OMIM: 182389](https://www.omim.org/entry/182389)
[Ensembl: ENSG00000136546](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136546)

📖 View canonical wiki page →

SCN1A Gene

SCN1A Gene

Gene Overview

SCN1A Gene

Gene Overview

Introduction

Protein Structure

Overall Architecture

Key Structural Features

Structural States

Normal Physiological Function

Action Potential Generation

Cellular Expression

Network Function

Disease Associations

Epilepsy

Dravet Syndrome

Genetic Epilepsy Syndromes

Pathogenic Mechanisms

Alzheimer's Disease

Autism Spectrum Disorders

Other Neurological Conditions

Channel Trafficking and Localization

Subcellular Distribution

Trafficking Mechanisms

Regulation by Ankyrin-G

Electrophysiological Properties

Key Parameters

Gating Kinetics

Comparative Biology

Evolutionary Conservation

Model Systems

Future Directions

Research Priorities

Unanswered Questions

Clinical Perspectives

Diagnosis and Testing

Management Strategies

Long-term Outcomes

Molecular Mechanisms

Channel Gating

Regulatory Mechanisms

Interaction with Auxiliary Subunits

Therapeutic Relevance

Anti-Epileptic Drugs

Challenges in Targeting Nav1.1

Emerging Therapies

Genetic Variants

Pathogenic Variants

Genotype-Phenotype Correlations

Research Directions

Current Focus Areas

Animal Models

Clinical Perspectives

Diagnosis

Management

Key Publications

See Also

External Links